drugset / Trial / NCT05494528
Comparing P1101 to Entecavir in Patients With HBeAg(-) Hepatitis B Under Long-term Nucleos(t)Ide Analogue Therapy
RandomizedParallel-groupOpen-labelTreatment
Summary
This is an open-label, multicenter, randomized, active control study, comparing P1101 monotherapy to entecavir monotherapy in patients with HBeAg-negative chronic hepatitis B under long-term nucleos(t)ide analogue therapy.
Timeline
- Start
- 2021-05-04
- Primary completion
- 2023-12-30
- Completion
- 2024-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Entecavir | Small molecule | 0.5 mg | — |
| Subject | Ropeginterferon alfa-2b | Protein / enzyme biologic | 450 ug | Subcutaneous |